DarioHealth Corp. develops digital health and digital therapeutics solutions for people managing chronic conditions. The company’s multi-condition platform uses data analytics, connected health devices, personalized interventions and one-on-one coaching across diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
DRIO news commonly covers quarterly financial results, conference calls, commercial activity with health plans, payers, self-insured employers, care providers and consumers, and clinical research based on real-world platform data. Other recurring updates include AI-enabled product development such as DarioIQ, evidence publications, board and governance changes, and capital or credit arrangements supporting the company’s digital health business.
DarioHealth (DRIO) expanded its contract with a regional grocery retailer to add Dario Women, its perimenopause and menopause support program. The expanded program will be offered to eligible insured employees in January 2027. The retailer has used Dario's cardiometabolic solution since the beginning of 2025 and selected the additional program following employee demand and an evaluation with its benefits consultant.
Dario Women launched in August 2026, combining behavioral coaching and access to licensed healthcare providers, with optional evaluation for hormone replacement therapy when medically appropriate. Dario said nearly 45% of its current book of business comprises women over age 40 who could potentially benefit, providing an opportunity to expand the program among existing clients. The company describes adding services to existing contracts as a way to increase revenue per customer with little incremental customer acquisition investment.
DarioHealth (DRIO) announced an Aon review supporting estimated annual healthcare cost reductions of 2.5% to 7.2% across a covered population.
The estimate measures total healthcare spending, not just participant spending. For a representative 20,000-life population, estimated savings are roughly $3.8 million to $10.8 million annually. Aon estimated that managing multiple conditions and providing physician access may add 1.6 to 2.8 percentage points of savings. A component study found $5,077 in annual savings and 23.5% fewer inpatient discharges per Dario user with type 2 diabetes versus matched non-users.
The review covered 17 studies identified by Dario, including independent and Dario-sponsored research. Aon did not independently verify underlying data, audit studies or evaluate all available evidence. Its findings support associations rather than guaranteed outcomes; results vary by population and other factors.
DarioHealth (DRIO) signed a new contract with a leading New Jersey health plan representing approximately 1.5 million covered lives, secured via channel partner Amwell.
The agreement covers deployment of Dario's cardiometabolic suite and provider-backed care, which is expected to launch and begin generating revenue in the first quarter of 2027. The customer is an administrative services only health plan, giving Dario access to a large population of self-funded employer groups. This is the third large state health plan Dario has signed through Amwell in the past 12 months, following contracts with major health insurers in Arizona and Florida, and it expands the reach of Dario's multi-condition digital health platform.
DarioHealth (NASDAQ: DRIO) reported second quarter 2026 revenue of $5.2 million, down from $5.4 million a year ago and $5.6 million in Q1 2026, mainly due to discontinuing certain pharmaceutical-related business as it shifts toward a B2B2C annual recurring revenue model.
Gross profit rose to $3.2 million and gross margin improved to about 62% versus 55% a year earlier, with non-GAAP B2B2C gross margin near 80% for the 10th straight quarter. Operating expenses fell 21% year-over-year to $9.7 million, improving operating loss to $6.5 million and net loss to $7.9 million. The company cited $13.1 million of contracted and late-stage ARR, more than 80% multi-condition, and highlighted new commercial wins including a top‑5 national health plan expansion, a fifth Fortune 50 client, and broader reach through Solera and Amwell channel partners.
Pro forma cash, cash equivalents and short‑term deposits totaled $36.8 million after raising $22.8 million net in a July 2026 at‑the‑market registered direct offering.
DarioHealth (NASDAQ: DRIO) announced the launch of two new provider-backed programs, Dario Women™ and Dario Sleep™, expanding its AI-enabled cardiometabolic platform into women's health and sleep. The programs integrate AI-powered engagement, human behavioral coaching and licensed healthcare providers to address perimenopause/menopause-related cardiometabolic risks and obstructive sleep apnea (OSA).
According to DarioHealth, both solutions are expected to roll out to Fortune 500 and other clients in Fall 2026, with recurring digital platform revenue per engaged member per month anticipated to begin in Q4 2026 and provider-backed care revenue expected from late 2026 into early 2027. The company aims to increase revenue opportunities with existing enterprise customers by offering additional high-cost clinical categories on the same integrated platform, which already covers diabetes, hypertension, weight management, musculoskeletal, behavioral health, women's health and sleep.
DarioHealth (Nasdaq: DRIO) announced it will release financial results for the second quarter ended June 30, 2026, on Tuesday, August 11, 2026, before the market opens. Management will host a conference call and webcast at 8:30 a.m. Eastern Time the same day.
The call will feature CEO Erez Raphael, COO Lara Dodo, and CFO Chen Franco-Yehuda. Investors can join via domestic dial-in 1-800-717-1738, international dial-in 1-646-307-1865, or the Call me™ and webcast links provided. A replay will be available through August 25, 2026.
DarioHealth (NASDAQ: DRIO) announced the launch of its Integrated GLP-1 Program, the first commercial product from its collaboration with Beluga Health. The offering combines Dario’s AI-powered chronic care platform with Beluga’s network of licensed providers to deliver evaluation, prescribing of FDA-approved GLP-1 medications when clinically appropriate, and ongoing clinical oversight in a single, end-to-end experience.
The program targets a shifting reimbursement environment where employers and health plans are moving from broad GLP-1 coverage to clinically managed models and more consumer-centric channels. Commercial availability is expected in Fall 2026, with revenue contribution anticipated late 2026 and ramping through 2027. Access will be through three channels: Dario’s MyDario direct-to-consumer shop, health plan marketplaces, and employer B2B2C programs. Dario reports its digital marketplace has served more than 1 million consumers over the last three years, and member interactions will feed blinded data into the DarioIQ AI engine, which is powered by more than 13 billion longitudinal healthcare data points, to support ongoing optimization of outcomes and payer cost savings.
DarioHealth (NASDAQ: DRIO) has priced a registered direct offering of 3,454,559 shares of common stock (or equivalents) at $6.80 per share, structured as an at-the-market transaction under Nasdaq rules. Expected gross proceeds are approximately $23.5 million before placement fees and expenses, with closing targeted on or about July 23, 2026 subject to customary conditions.
A member of the board of directors is participating by purchasing 14,430 shares at $6.93 per share. According to DarioHealth, net proceeds are intended for working capital, investments, acquisitions and general corporate purposes. The securities are being issued off an effective Form S-3 shelf registration (File No. 333-294454), with A.G.P./Alliance Global Partners acting as sole placement agent. The company highlights participation from existing long-term institutional investors alongside a new global fundamental institutional investor.
DarioHealth (NASDAQ: DRIO) announced that a Fortune 50 employer has awarded the company a contract to provide its integrated, AI-powered digital cardiometabolic care platform for employees with diabetes and/or hypertension. The program will cover more than 100,000 eligible employees and is expected to launch in Fall 2026.
According to DarioHealth, annual recurring revenue from this program is expected to begin by year-end 2026 and increase through 2027 and beyond. This is Dario’s fifth Fortune 50 client, and nearly one-quarter of its clients are Fortune 500 companies. The platform targets comorbid chronic conditions using connected devices, human coaching and AI-driven insights via DarioIQ.
DarioHealth (NASDAQ: DRIO) announced that broader deployment of its proprietary AI engine DarioIQ™ is expected to increase annual B2B2C recurring revenue from existing customers by approximately 10%–15%, excluding any impact from future customer wins or condition expansions.
According to DarioHealth, DarioIQ’s AI-driven personalization increased active member engagement by 40% and improved member retention by 20% versus a control group, based on development completed in the first half of 2026. The company reports a program ROI of 2.5x–5x across its solutions.
DarioIQ uses more than 13 billion de-identified proprietary real-world healthcare data points, combining biometric readings from FDA-cleared devices, clinical history and behavioral patterns to optimize outreach. DarioHealth highlights responsible-AI practices and notes that its recent expansion into provider-backed care is expected to connect AI-driven engagement more directly to clinical intervention and reimbursement workflows.